Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story

Simply Wall St.02-20

Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy. Casgevy is approved for sickle cell disease and beta thalassemia,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612996282?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","is_english":true,"pubTime":"2026-02-20 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612996282","market":"nz","top_or_hot":-1,"title":"Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story","media":"Simply Wall St.","content":"<div>\n<p>Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy. Casgevy is approved for sickle cell disease and beta thalassemia,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-casgevy-rollout-tests-gene-editing-role-in-vertex-ear\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-casgevy-rollout-tests-gene-editing-role-in-vertex-ear><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy. Casgevy is approved for sickle cell disease and beta thalassemia,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-casgevy-rollout-tests-gene-editing-role-in-vertex-ear\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERX","symbol_name":"Vertex, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-casgevy-rollout-tests-gene-editing-role-in-vertex-ear","article_id":"2612996282","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-casgevy-rollout-tests-gene-editing-role-in-vertex-ear","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612996282","pubTimestamp":1771522445,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy.\nCasgevy is approved for sickle cell disease and beta thalassemia, marking a key step in bringing gene-editing into routine clinical use.\nThe current focus is on moving from approval to broader real-world deployment across eligible patient populations.\n\nFor you as an investor, Casgevy sits at the intersection of Vertex's established role in serious diseases...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VERX":"Vertex, Inc.","VRTX":"福泰制药"},"translate_title":"Vertex Casgevy的推出测试了基因编辑在Vertex财报中的作用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1.5,"VERX":1.5},"content_text":"Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy. Casgevy is approved for sickle cell disease and beta thalassemia, marking a key step in bringing gene-editing into routine clinical use. The current focus is on moving from approval to broader real-world deployment across eligible patient populations.  For you as an investor, Casgevy sits at the intersection of Vertex's established role in serious diseases and the growing use of gene-editing tools in medicine. While Vertex is already known for its work in other therapeutic areas, Casgevy adds exposure to a treatment approach that targets the underlying genetic drivers of disease rather than only managing symptoms. The scale and pace of Casgevy uptake could influence how investors think about NasdaqGS:VRTX and gene-editing companies more broadly over time. As more patients start treatment, the focus is likely to stay on how smoothly the real-world rollout proceeds, patient access, and how payers respond to this kind of high-complexity therapy. Stay updated on the most important news stories for Vertex Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Vertex Pharmaceuticals. NasdaqGS:VRTX Earnings & Revenue Growth as at Feb 2026 📰 Beyond the headline: 0 risks and 3 things going right for Vertex Pharmaceuticals that every investor should see. For Vertex, scaling up Casgevy treatments with CRISPR Therapeutics looks like a concrete step in shifting from a cystic fibrosis focused story to one where gene-editing and non CF products play a bigger role. Management is already pointing to at least US$500 million in 2026 revenue from non CF products, with Casgevy specifically called out alongside JOURNAVX. That sits next to full year 2025 revenue of US$12.0b and a move from a US$535.6 million net loss to US$3.95b in net income, which shows the company now has meaningful earnings support for these newer launches. AdvertisementHow This Fits Into The Vertex Pharmaceuticals Narrative  Casgevy uptake adds weight to the narrative that Vertex can use its cystic fibrosis cash flows to build a broader precision medicine portfolio, including gene-editing for blood disorders. If real world adoption of Casgevy or reimbursement terms are slower than Vertex anticipates, that could challenge expectations that new launches will materially expand earnings beyond the core cystic fibrosis franchise. The specific revenue contribution from Casgevy within the US$500 million non CF guidance, and how that compares with ALYFTREK and JOURNAVX, is not fully detailed in the narrative and may become more important as reported figures break this out.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Vertex Pharmaceuticals to help decide what it is worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Execution risk as Vertex and CRISPR Therapeutics move Casgevy from initial approvals into wider commercial use, including complex manufacturing and treatment center coordination. ⚠️ Uncertainty around long term payer acceptance and pricing for high complexity gene-editing therapies, which could limit how large the addressable revenue pool becomes. 🎁 Casgevy gives Vertex exposure to gene-editing alongside larger peers such as Pfizer and Regeneron that are also active in genetic medicines, potentially broadening future revenue beyond cystic fibrosis. 🎁 Management is guiding to US$12.95b to US$13.1b of 2026 revenue with at least US$500 million from non CF products, showing Casgevy is already part of a more diversified earnings mix.  What To Watch Going Forward From here, it makes sense to watch how quickly Vertex ramps patient infusions through its authorized treatment center network, how much of the non CF revenue bucket Casgevy represents as quarterly disclosures build up, and whether real world outcomes support broader use. You can also pay attention to how competitors in genetic medicine, such as CRISPR-focused peers and larger biopharma companies, respond with their own treatments and pricing. Any commentary from management at investor events on treatment volumes, reimbursement progress, and long term follow up data will be important signals for how central Casgevy could become in the Vertex story. To ensure you are always in the loop on how the latest news impacts the investment narrative for Vertex Pharmaceuticals, head to the\ncommunity page for Vertex Pharmaceuticals to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612996282","isCrawlerRequest":true}